@entity120 in @entity8674 major and the role of XXXX therapy.

@entity1 @entity844 @entity6211 @entity120 @entity299 @entity204 @entity8674
@entity299 , such as @entity120 ( @entity120 ), are the leading cause of @entity204 in @entity8674 @entity1 . @entity6211 , due to its role in @entity844 oxidation, might help control the elevation in pulmonary artery systolic pressure (PASP). The objectives of this study were to assess the prevalence of @entity120 in @entity8674 major @entity1 , identify clinical predictors for its development, and determine the potential effects of @entity6211 . In total, 32 @entity1 with @entity8674 major were recruited; 16 age- and sex-matched @entity1 constituted the control group. Cardiac evaluation was performed by using echocardiography. The @entity1 with @entity120 received 50 mg/kg/day @entity6211 orally for 3 months and were then reevaluated. Based on PASP, the @entity1 were divided into group A without @entity120 and group B with @entity120 . The prevalence of @entity120 was 37.5%. The other echocardiographic measurements were not significantly different between groups A and B. PASP did not have any significant correlation with the following variables: age, total number of blood units received, splenic status, serum ferritin level, and ejection fraction. Following the administration of @entity6211 , there was a significant decrease in the mean PASP from 33.96 +/- 7.85 to 24.11 +/- 7.61. All cardiac dimensions decreased following @entity6211 , but the changes were not statistically significant. Even though @entity8674 major resulted in an elevation in the PASP in only a fraction of the @entity1 , it seems to have an impact on the heart dimensions and function of all @entity1 . No clinical predictors were identified. Oral administration of @entity6211 appears to significantly improve PASP.
